title: European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.
authors: Department of Cardiology, Charité-Universitätsmedizin Berlin (CBF), Hindenburgdamm 30, 12203 Berlin, Berlin Institute of Health (BIH), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Germany.
authors: Ulf
authors: U
authors: Landmesser
authors: National Institute for Health and Medical Research (INSERM), University of Pierre and Marie Curie, Pitié-Salpêtrière Hospital, 47 Hôpital boulevard, Paris, 75013 France.
authors: M. John
authors: MJ
authors: Chapman
authors: Lipid Clinic, Point Medical, Dijon, France.
authors: Michel
authors: M
authors: Farnier
authors: Cardiology Division, Department of Specialties in Medicine, Geneva University Hospitals, 4, rue Gabrielle-Perret-GentilCH - 1211 Geneva, Switzerland.
authors: Baris
authors: B
authors: Gencer
authors: Department of Internal Medicine III, Martin-Luther-University Halle/Wittenberg, University Hospital, Dept. of Int. Medicine III, Universitätsring 19/2006108, Halle/Saale, Germany.
authors: Stephan
authors: S
authors: Gielen
authors: Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
authors: G Kees
authors: GK
authors: Hovingh
authors: University Heart Center, Cardiology Clinic, University Hospital Zurich, Rämistrasse 100, 8091 Zurich and Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
authors: Thomas F
authors: TF
authors: Lüscher
authors: Department of Cardiology, Charité-Universitätsmedizin Berlin (CBF), Hindenburgdamm 30, 12203 Berlin, Berlin Institute of Health (BIH), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Germany.
authors: David
authors: D
authors: Sinning
authors: Hacettepe University, Faculty of Medicine, Sihhiye, Ankara, Turkey.
authors: Lale
authors: L
authors: Tokgözoglu
authors: Sahlgrenska University Hospital, SE-413 45 Gothenburg, Sweden.
authors: Olov
authors: O
authors: Wiklund
authors: Department of Cardiology, University Hospital Ramón y Cajal, Colmenar Viejo Road, Km. 9.1, Madrid, Spain.
authors: Jose Luis
authors: JL
authors: Zamorano
authors: Cardiology Department, CCUL, CAML, Faculdade de Medicina, Universidade de Lisboa, Alameda da Universidade, Lisboa, Portugal.
authors: Fausto J
authors: FJ
authors: Pinto
authors: Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti 9, 20133 Milan and Multimedica IRCSS Milano, Milan, Italy.
authors: Alberico L
authors: AL
authors: Catapano
mesh_terms: D002309:Cardiology / Q000458:organization & administration; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood; D032921:Consensus; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control; D000091362:PCSK9 Inhibitors; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D000071449:Proprotein Convertase 9
chemical_list: D002317:Cardiovascular Agents; D002784:Cholesterol; D004791:Enzyme Inhibitors; D000091362:PCSK9 Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9